1. Cardiac hyaluronan may be associated with the persistence of atrial fibrillation
- Author
-
Morio Shoda, Ayako Okada, Yuichiro Kashima, Takahiro Takeuchi, Wataru Shoin, Koichiro Kuwahara, Yasutaka Oguchi, Hiroshi Imamura, Koji Yoshie, Takeshi Tomita, and Kenichi Nitta
- Subjects
0301 basic medicine ,Male ,medicine.medical_specialty ,Inflammation ,Enzyme-Linked Immunosorbent Assay ,030204 cardiovascular system & hematology ,medicine.disease_cause ,03 medical and health sciences ,0302 clinical medicine ,Interquartile range ,Internal medicine ,Atrial Fibrillation ,Medicine ,Humans ,Hyaluronic Acid ,Coronary sinus ,Retrospective Studies ,business.industry ,Myocardium ,Atrial fibrillation ,Middle Aged ,Brain natriuretic peptide ,medicine.disease ,Prognosis ,Peripheral ,Cardiac surgery ,Oxidative Stress ,030104 developmental biology ,Endocrinology ,Echocardiography ,Cardiology ,Female ,medicine.symptom ,Cardiology and Cardiovascular Medicine ,business ,Oxidative stress ,Biomarkers - Abstract
Hyaluronan (HA), a primary component of the extracellular matrix, is associated with several cardiovascular diseases. However, its precise cardiac origin and role in atrial fibrillation (AF) remain unclear. We investigated chamber-specific HA levels in patients with paroxysmal AF (PAF) or persistent AF (PSAF). The levels of HA, a diacron-reactive oxygen metabolite (dROM) as a marker for oxidative stress, at different cardiac sites, and peripheral brain natriuretic peptide (BNP) levels were measured in patients with PAF (n = 50) or PSAF (n = 35). HA levels in the coronary sinus (CS-HA) were significantly higher than those other sites, in both PAF and PSAF patients, and CS-HA levels were significantly higher in PSAF patients than in PAF patients [37.1 (interquartile range, 31.2–48.3) vs. 30.6 (23.7–40.2) pg/mL, P
- Published
- 2016